Cargando…
Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters
Rivastigmine is a drug commonly used in the management of Alzheimer’s disease that shows bioavailability problems. To overcome this, the use of nanosystems, such as nanostructured lipid carriers (NLC), administered through alternative routes seems promising. In this work, we performed a double optim...
Autores principales: | Cunha, Sara, Costa, Cláudia Pina, Loureiro, Joana A., Alves, Jorge, Peixoto, Andreia F., Forbes, Ben, Sousa Lobo, José Manuel, Silva, Ana Catarina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407548/ https://www.ncbi.nlm.nih.gov/pubmed/32605177 http://dx.doi.org/10.3390/pharmaceutics12070599 |
Ejemplares similares
-
Improving Drug Delivery for Alzheimer’s Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels
por: Cunha, Sara, et al.
Publicado: (2021) -
Novel Phenobarbital-Loaded Nanostructured Lipid Carriers for Epilepsy Treatment: From QbD to In Vivo Evaluation
por: Scioli-Montoto, Sebastian, et al.
Publicado: (2022) -
In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN)
por: Costa, Cláudia Pina, et al.
Publicado: (2021) -
QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics
por: Arora, Deepshi, et al.
Publicado: (2022) -
Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product
por: Pielenhofer, Jonas, et al.
Publicado: (2023)